{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:29:40Z","timestamp":1791289780075,"version":"4.3.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/nrneph.2016.99","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T07:06:05Z","timestamp":1469430365000},"page":"563-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Anti-complement-factor H-associated glomerulopathies"],"prefix":"10.1038","volume":"12","author":[{"given":"Marie-Agnes Dragon","family":"Durey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambhuprasad Kotresh","family":"Togarsimalemath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"BFnrneph201699_CR1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 344, 1058\u20131066 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201699_CR2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","volume":"36","author":"C Mele","year":"2014","unstructured":"Mele, C., Remuzzi, G. & Noris, M. Hemolytic uremic syndrome. Semin. Immunopathol. 36, 399\u2013420 (2014).","journal-title":"Semin. Immunopathol."},{"key":"BFnrneph201699_CR3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.04961107","volume":"3","author":"J Cerda","year":"2008","unstructured":"Cerda, J. et al. Epidemiology of acute kidney injury. Clin. J. Am. Soc. Nephrol. 3, 881\u2013886 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","volume":"6","author":"C Loirat","year":"2011","unstructured":"Loirat, C. & Fr\u00e9meaux-Bacchi, V. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 6, 60 (2011).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFnrneph201699_CR5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi, S. & Fervenza, F. C. Membranoproliferative glomerulonephritis \u2014 a new look at an old entity. N. Engl. J. Med. 366, 1119\u20131131 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201699_CR6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering, M. C. et al. C3 glomerulopathy: consensus report. Kidney Int. 84, 1079\u20131089 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph201699_CR7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais, A. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454\u2013464 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph201699_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","volume":"67","author":"PF Zipfel","year":"2015","unstructured":"Zipfel, P. F. et al. The role of complement in C3 glomerulopathy. Mol. Immunol. 67, 21\u201330 (2015).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.humpath.2010.11.023","volume":"42","author":"A Servais","year":"2011","unstructured":"Servais, A. et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum. Pathol. 42, 1305\u20131311 (2011).","journal-title":"Hum. Pathol."},{"key":"BFnrneph201699_CR10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molimm.2004.02.005","volume":"41","author":"S Rodr\u00edguez de C\u00f3rdoba","year":"2004","unstructured":"Rodr\u00edguez de C\u00f3rdoba, S., Esparza-Gordillo, J., Goicoechea de Jorge, E., Lopez-Trascasa, M. & S\u00e1nchez-Corral, P. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41, 355\u2013367 (2004).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ni.1755","volume":"10","author":"J Wu","year":"2009","unstructured":"Wu, J., Wu, Y. Q., Ricklin, D., Janssen, B. J. & Lambris, J. D. & Gros, P. Structure of complement fragment C3b\u2013factor H and implications for host protection by complement regulators. Nat. Immunol. 10, 728\u2013733 (2009).","journal-title":"Nat. Immunol."},{"key":"BFnrneph201699_CR12","doi-asserted-by":"crossref","first-page":"12839","DOI":"10.1073\/pnas.1102167108","volume":"108","author":"P Roversi","year":"2011","unstructured":"Roversi, P. et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc. Natl Acad. Sci. USA 108, 12839\u201312844 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph201699_CR13","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.molimm.2010.03.007","volume":"47","author":"A Bhattacharjee","year":"2010","unstructured":"Bhattacharjee, A., Lehtinen, M. J., Kajander, T., Goldman, A. & Jokiranta, T. S. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d. Mol. Immunol. 47, 1686\u20131691 (2010).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR14","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1073\/pnas.1017087108","volume":"108","author":"T Kajander","year":"2011","unstructured":"Kajander, T. et al. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl Acad. Sci. USA 108, 2897\u20132902 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph201699_CR15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1107\/S0907444911015423","volume":"67","author":"HP Morgan","year":"2011","unstructured":"Morgan, H. P. et al. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H. Acta Crystallogr. D Biol. Crystallogr. 67, 593\u2013600 (2011).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"BFnrneph201699_CR16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","volume":"16","author":"MA Dragon-Durey","year":"2005","unstructured":"Dragon-Durey, M. A. et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 555\u2013563 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR17","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","volume":"114","author":"C Abarrategui-Garrido","year":"2009","unstructured":"Abarrategui-Garrido, C. et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114, 4261\u20134271 (2009).","journal-title":"Blood"},{"key":"BFnrneph201699_CR18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha, A. et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 85, 1151\u20131160 (2014).","journal-title":"Kidney Int."},{"key":"BFnrneph201699_CR19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.01260212","volume":"8","author":"J Hofer","year":"2013","unstructured":"Hofer, J. et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 8, 407\u2013415 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ped.12549","volume":"57","author":"M Lee","year":"2014","unstructured":"Lee, M. et al. Atypical hemolytic uremic syndrome: a Korean pediatric series. Pediatr. Int. 57, 431\u2013438 (2014).","journal-title":"Pediatr. Int."},{"key":"BFnrneph201699_CR21","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey, M. A. et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 21, 2180\u20132187 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","volume":"115","author":"I Moore","year":"2010","unstructured":"Moore, I. et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115, 379\u2013387 (2010).","journal-title":"Blood"},{"key":"BFnrneph201699_CR23","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris, M. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5, 1844\u20131859 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","volume":"27","author":"LM Geerdink","year":"2012","unstructured":"Geerdink, L. M. et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr. Nephrol. 27, 1283\u20131291 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR25","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","volume":"111","author":"M Jozsi","year":"2008","unstructured":"Jozsi, M. et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency. Blood 111, 1512\u20131514 (2008).","journal-title":"Blood"},{"key":"BFnrneph201699_CR26","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","volume":"3","author":"PF Zipfel","year":"2007","unstructured":"Zipfel, P. F. et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3, e41 (2007).","journal-title":"PLoS Genet."},{"key":"BFnrneph201699_CR27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi, V. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8, 554\u2013562 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","volume":"46","author":"MA Dragon-Durey","year":"2009","unstructured":"Dragon-Durey, M. A. et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical hemolytic uremic syndrome. J. Med. Genet. 46, 447\u2013450 (2009).","journal-title":"J. Med. Genet."},{"key":"BFnrneph201699_CR29","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/ndt\/gfq010","volume":"25","author":"D Westra","year":"2010","unstructured":"Westra, D. et al. Genetic disorders in complement (regulating) genes in patients with atypical hemolytic uremic syndrome (aHUS). Nephrol. Dial. Transplant. 25, 2195\u20132202 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201699_CR30","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00467-010-1446-9","volume":"25","author":"PF Zipfel","year":"2010","unstructured":"Zipfel, P. F. et al. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr. Nephrol. 25, 2009\u20132019 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/ndt\/gfp388","volume":"25","author":"S Strobel","year":"2010","unstructured":"Strobel, S. et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical hemolytic uremic syndrome. Nephrol. Dial. Transplant. 25, 136\u2013144 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201699_CR32","first-page":"223","volume":"52","author":"N Guan","year":"2014","unstructured":"Guan, N. et al. Clinical characteristics of atypical hemolytic uremic syndrome associated with H factor antibody in children. Zhonghua Er Ke Za Zhi 52, 223\u2013226 (in Chinese) (2014).","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"BFnrneph201699_CR33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00467-014-2948-7","volume":"30","author":"P Khandelwal","year":"2015","unstructured":"Khandelwal, P. et al. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr. Nephrol. 30, 451\u2013457 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2215\/CJN.05750611","volume":"7","author":"D Kavanagh","year":"2012","unstructured":"Kavanagh, D. et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin. J. Am. Soc. Nephrol. 7, 417\u2013426 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-1229(90)90018-L","volume":"57","author":"RE Spitzer","year":"1990","unstructured":"Spitzer, R. E., Stitzel, A. E. & Tsokos, G. C. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clin. Immunol. Immunopathol. 57, 10\u201318 (1990).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"BFnrneph201699_CR36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2012.05.009","volume":"52","author":"TH Goodship","year":"2012","unstructured":"Goodship, T. H. et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol. Immunol. 52, 200\u2013206 (2012).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ckj\/sfs002","volume":"5","author":"P Nozal","year":"2012","unstructured":"Nozal, P. et al. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin. Kidney J. 5, 133\u2013136 (2012).","journal-title":"Clin. Kidney J."},{"key":"BFnrneph201699_CR38","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","volume":"194","author":"C Blanc","year":"2015","unstructured":"Blanc, C. et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J. Immunol. 194, 5129\u20135138 (2015).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2249.1994.tb06530.x","volume":"95","author":"H Ohi","year":"1994","unstructured":"Ohi, H. & Yasugi, T. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin. Exp. Immunol. 95, 316\u2013321 (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph201699_CR40","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","volume":"47","author":"S Strobel","year":"2010","unstructured":"Strobel, S., Zimmering, M., Papp, K., Prechl, J. & J\u00f3zsi, M. Anti-factor B autoantibody in dense deposit disease. Mol. Immunol. 47, 1476\u20131483 (2010).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR41","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1056\/NEJMc1107484","volume":"365","author":"Q Chen","year":"2011","unstructured":"Chen, Q. et al. Combined C3b and factor B autoantibodies and MPGN type II. N. Eng. J. Med. 365, 2340\u20132342 (2011).","journal-title":"N. Eng. J. Med."},{"key":"BFnrneph201699_CR42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.molimm.2015.06.021","volume":"67","author":"ME Bernab\u00e9u-Herrero","year":"2015","unstructured":"Bernab\u00e9u-Herrero, M. E. et al. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol. Immunol. 67, 276\u2013286 (2015).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10157-010-0375-z","volume":"15","author":"E Matsukuma","year":"2011","unstructured":"Matsukuma, E. et al. A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations. Clin. Exp. Nephrol. 15, 269\u2013274 (2011).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph201699_CR44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","volume":"29","author":"D Noone","year":"2014","unstructured":"Noone, D. et al. Successful treatment of DEAP-HUS with eculizumab. Pediatr. Nephrol. 29, 841\u2013851 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR45","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","volume":"133","author":"BD Chiodini","year":"2014","unstructured":"Chiodini, B. D. et al. Eculizumab in anti-factor H antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 133, e1764\u2013e1768 (2014).","journal-title":"Pediatrics"},{"key":"BFnrneph201699_CR46","first-page":"86","volume":"55","author":"A Uslu-G\u00f6kceog\u02d8lu","year":"2013","unstructured":"Uslu-G\u00f6kceog\u02d8lu, A., Dog\u02d8an, C. S., \u00c7omak, E., Koyun, M. & Akman, S. Atypical hemolytic uremic syndrome due to factor H autoantibody. Turk. J. Pediatr. 55, 86\u201389 (2013).","journal-title":"Turk. J. Pediatr."},{"key":"BFnrneph201699_CR47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-015-1142-y","volume":"20","author":"N Ito","year":"2016","unstructured":"Ito, N. et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin. Exp. Nephrol. 20, 265\u2013272 (2016).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph201699_CR48","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/ndt\/gfp166","volume":"24","author":"T Kwon","year":"2009","unstructured":"Kwon, T., Belot, A. & Ranchin, B. Varicella as a trigger of atypical hemolyticuremic syndrome associated with complement dysfunction: two cases. Nephrol. Dial. Transplant. 24, 2752\u20132754 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201699_CR49","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","volume":"55","author":"O Boyer","year":"2010","unstructured":"Boyer, O. et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am. J. Kidney Dis. 55, 923\u2013927 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201699_CR50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","volume":"66","author":"BH Lee","year":"2009","unstructured":"Lee, B. H. et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency. Pediatr. Res. 66, 336\u2013340 (2009).","journal-title":"Pediatr. Res."},{"key":"BFnrneph201699_CR51","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1600-6143.2009.02586.x","volume":"9","author":"M Le Quintrec","year":"2009","unstructured":"Le Quintrec, M. et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am. J. Transplant. 9, 1223\u20131229 (2009).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201699_CR52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/aji.12404","volume":"74","author":"D Song","year":"2015","unstructured":"Song, D. et al. Overactivation of complement alternative pathway in postpartum atypical hemolytic uremic syndrome patients with renal involvement. Am. J. Reprod. Immunol. 74, 345\u2013356 (2015).","journal-title":"Am. J. Reprod. Immunol."},{"key":"BFnrneph201699_CR53","first-page":"833","volume":"51","author":"P Khandelwal","year":"2014","unstructured":"Khandelwal, P., Sinha, A., Hari, P. & Bagga, A. Plasma exchanges and immunosuppression for anti-complement factor H associated hemolytic uremic syndrome. Indian Pediatr. 51, 833\u2013835 (2014).","journal-title":"Indian Pediatr."},{"key":"BFnrneph201699_CR54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5414\/CN107777","volume":"83","author":"JJ Kim","year":"2015","unstructured":"Kim, J. J. et al. The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies. Clin. Nephrol. 83, 49\u201356 (2015).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201699_CR55","first-page":"1017","volume":"22","author":"A Gupta","year":"2011","unstructured":"Gupta, A. et al. Diarrhea related hemolytic uremic syndrome: unmasking anti-factor H antibodies. Saudi J. Kidney Dis. Transpl. 22, 1017\u20131018 (2011).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"BFnrneph201699_CR56","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1542\/peds.2012-0903","volume":"131","author":"M Malina","year":"2013","unstructured":"Malina, M. et al. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131, e331\u2013e335 (2013).","journal-title":"Pediatrics"},{"key":"BFnrneph201699_CR57","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.ajkd.2013.09.020","volume":"63","author":"G Ardissino","year":"2014","unstructured":"Ardissino, G. et al. Skin involvement in atypical hemolytic uremic syndrome. Am. J. Kidney Dis. 63, 652\u2013655 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201699_CR58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.ajkd.2015.03.039","volume":"66","author":"C Rigothier","year":"2015","unstructured":"Rigothier, C. et al. Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgA\u03bb antibody. Am. J. Kidney Dis. 66, 331\u2013336 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201699_CR59","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1186\/1752-1947-5-598","volume":"5","author":"D Patschan","year":"2011","unstructured":"Patschan, D. et al. Idiopathic combined, autoantibody-mediated ADAMTS-13\/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report. J. Med. Case Rep. 5, 598 (2011).","journal-title":"J. Med. Case Rep."},{"key":"BFnrneph201699_CR60","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1158\/1078-0432.CCR-10-0321","volume":"16","author":"N Amornsiripanitch","year":"2010","unstructured":"Amornsiripanitch, N. et al. Complement factor H autoantibodies are associated with early stage NSCLC. Clin. Cancer Res. 16, 3226\u20133231 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrneph201699_CR61","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar3549","volume":"14","author":"A FoltynZadura","year":"2012","unstructured":"FoltynZadura, A. et al. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res. Ther. 14, R1 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrneph201699_CR62","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","volume":"122","author":"S Jodele","year":"2013","unstructured":"Jodele, S. et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 122, 2003\u20132007 (2013).","journal-title":"Blood"},{"key":"BFnrneph201699_CR63","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1167\/iovs.09-5124","volume":"51","author":"B Dhillon","year":"2010","unstructured":"Dhillon, B. et al. Complement factor H auto-antibodies and age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 51, 5858\u20135863 (2010).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnrneph201699_CR64","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1084\/jem.167.2.664","volume":"167","author":"J Rey-Campos","year":"1988","unstructured":"Rey-Campos, J., Rubinstein, P. & Rodriguez de Cordoba, S. A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP. J. Exp. Med. 167, 664\u2013669 (1988).","journal-title":"J. Exp. Med."},{"key":"BFnrneph201699_CR65","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/eji.1830210337","volume":"21","author":"C Estaller","year":"1991","unstructured":"Estaller, C., Schwaeble, W., Dierich, M. & Weiss, E. H. Human complement fH: two fH proteins are derived from alternatively spliced transcripts. Eur. J. Immunol. 21, 799\u2013802 (1991).","journal-title":"Eur. J. Immunol."},{"key":"BFnrneph201699_CR66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","volume":"56","author":"C Skerka","year":"2013","unstructured":"Skerka, C., Chen, Q., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement factor H related proteins (CFHRs). Mol. Immunol. 56, 170\u2013180 (2013).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/humu.9408","volume":"27","author":"S Heinen","year":"2006","unstructured":"Heinen, S. et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum. Mutat. 27, 292\u2013293 (2006).","journal-title":"Hum. Mutat."},{"key":"BFnrneph201699_CR68","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1371\/journal.pmed.0030431","volume":"3","author":"JP Venables","year":"2006","unstructured":"Venables, J. P. et al. Atypical hemolytic uremic syndrome associated with a hybrid complement gene. PLoS Med. 3, e431 (2006).","journal-title":"PLoS Med."},{"key":"BFnrneph201699_CR69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0014-5793(99)01554-9","volume":"462","author":"J Hellwage","year":"1999","unstructured":"Hellwage, J. et al. Functional properties of complement fH-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 462, 345\u2013352 (1999).","journal-title":"FEBS Lett."},{"key":"BFnrneph201699_CR70","first-page":"174","volume":"40","author":"SA Majno","year":"2003","unstructured":"Majno, S. A., Jokiranta, T. S., Huehn, M., Seeberger, H. & Hellwage, J. The human FH-related protein 1 (FHR-1) binds to C3b and heparin: implications for a regulatory role on the level of C3 [abstract]. Mol. Immunol. 40, 174 (2003).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR71","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.4049\/jimmunol.174.10.6250","volume":"174","author":"JL McRae","year":"2005","unstructured":"McRae, J. L. et al. Human fH-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J. Immunol. 174, 6250\u20136256 (2005).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR72","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood-2009-02-205641","volume":"114","author":"S Heinen","year":"2009","unstructured":"Heinen, S. et al. Factor H related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114, 2439\u20132447 (2009).","journal-title":"Blood"},{"key":"BFnrneph201699_CR73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2011.152","volume":"80","author":"S Strobel","year":"2011","unstructured":"Strobel, S. et al. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 80, 397\u2013404 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph201699_CR74","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","volume":"189","author":"C Blanc","year":"2012","unstructured":"Blanc, C. et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J. Immunol. 189, 3528\u20133537 (2012).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR75","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1074\/jbc.M114.630871","volume":"290","author":"A Bhattacharjee","year":"2015","unstructured":"Bhattacharjee, A. et al. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H related protein 1 supporting a novel model for induction of autoimmunity in this disease. J. Biol. Chem. 290, 9500\u20139510 (2015).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph201699_CR76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molimm.2015.12.005","volume":"70","author":"P Nozal","year":"2015","unstructured":"Nozal, P. et al. Heterogeneity but individual constancy of epitopes isotypes and avidity of factor H autoantibodies inatypical hemolytic uremic syndrome. Mol. Immunol. 70, 47\u201355 (2015).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR77","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","volume":"110","author":"M J\u00f3zsi","year":"2007","unstructured":"J\u00f3zsi, M. et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110, 1516\u20131518 (2007).","journal-title":"Blood"},{"key":"BFnrneph201699_CR78","doi-asserted-by":"crossref","first-page":"e00146","DOI":"10.1042\/BSR20140117","volume":"34","author":"E Rodriguez","year":"2014","unstructured":"Rodriguez, E., Rallapalli, P. M., Osborne, A. J. & Perkins, S. J. New functional and structural insights from updated mutational databases for complement factor H, factor I, membrane cofactor protein and C3. Biosci. Rep. 34, e00146 (2014).","journal-title":"Biosci. Rep."},{"key":"BFnrneph201699_CR79","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","volume":"40","author":"S Rodr\u00edguez de C\u00f3rdoba","year":"2014","unstructured":"Rodr\u00edguez de C\u00f3rdoba, S., Hidalgo, M. S., Pinto, S. & Tortajada, A. Genetics of atypicalhemolyticuremic syndrome (aHUS). Semin. Thromb. Hemost. 40, 422\u2013430 (2014).","journal-title":"Semin. Thromb. Hemost."},{"key":"BFnrneph201699_CR80","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.4049\/jimmunol.1200357","volume":"189","author":"A Kopp","year":"2012","unstructured":"Kopp, A., Strobel, S. & Tortajada, A. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor H and factor H-related protein 1 to pentraxin 3. J. Immunol. 189, 1858\u20131867 (2012).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR81","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.4049\/jimmunol.181.12.8433","volume":"181","author":"L Deban","year":"2008","unstructured":"Deban, L. et al. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J. Immunol. 181, 8433\u20138440 (2008).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR82","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.4049\/jimmunol.163.7.3957","volume":"163","author":"H Jarva","year":"1999","unstructured":"Jarva, H., Jokiranta, T. S., Hellwage, J., Zipfel, P. F. & Meri, S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8\u201311. J. Immunol. 163, 3957\u20133962 (1999).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","volume":"43","author":"AG Gharavi","year":"2011","unstructured":"Gharavi, A. G. et al. Genome wide association study identifies susceptibility loci for IgA nephropathy. Nat. Genet. 43, 321\u2013327 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrneph201699_CR84","doi-asserted-by":"crossref","first-page":"e1002079","DOI":"10.1371\/journal.pgen.1002079","volume":"7","author":"J Zhao","year":"2011","unstructured":"Zhao, J. et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 7, e1002079 (2011).","journal-title":"PLoS Genet."},{"key":"BFnrneph201699_CR85","doi-asserted-by":"crossref","first-page":"e60352","DOI":"10.1371\/journal.pone.0060352","volume":"8","author":"LV Holmes","year":"2013","unstructured":"Holmes, L. V. et al. Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32. PLoS ONE 8, e60352 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneph201699_CR86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1744-313X.2011.01071.x","volume":"39","author":"N Leban","year":"2012","unstructured":"Leban, N. et al. Factor H and CFHR1 polymorphisms associated with atypical hemolytic uremic syndrome are differently expressed in Tunisian and Caucasian populations. Int. J. Immunogenet. 39, 110\u2013113 (2012).","journal-title":"Int. J. Immunogenet."},{"key":"BFnrneph201699_CR87","doi-asserted-by":"crossref","first-page":"e1003308","DOI":"10.1371\/journal.ppat.1003308","volume":"9","author":"T Meri","year":"2013","unstructured":"Meri, T. et al. Microbes bind complement inhibitor factor H via a common site. PLoS Pathog. 9, e1003308 (2013).","journal-title":"PLoS Pathog."},{"key":"BFnrneph201699_CR88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","volume":"219","author":"R Watson","year":"2014","unstructured":"Watson, R. et al. Standardisation of the factor H autoantibody assay. Immunobiology 219, 9\u201316 (2014).","journal-title":"Immunobiology"},{"key":"BFnrneph201699_CR89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","volume":"29","author":"G Sana","year":"2014","unstructured":"Sana, G. et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr. Nephrol. 29, 75\u201383 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR90","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino, G. et al. Discontinuation of eculizumab maintenance treatment for atypicalhemolyticuremic syndrome: a report of 10 cases. Am. J. Kidney Dis. 64, 633\u2013637 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201699_CR91","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1093\/nar\/gkg509","volume":"31","author":"PC Ng","year":"2003","unstructured":"Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812\u20133814 (2003).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneph201699_CR92","first-page":"20","volume":"7","author":"I Adzhubei","year":"2013","unstructured":"Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 7, 20 (2013).","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"BFnrneph201699_CR93","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","volume":"119","author":"LT Roumenina","year":"2012","unstructured":"Roumenina, L. T. et al. A prevalent C3 mutation in HUS patients causes a direct C3 convertase gain of-function. Blood 119, 4182\u20134191 (2012).","journal-title":"Blood"},{"key":"BFnrneph201699_CR94","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/jmg.40.9.676","volume":"40","author":"HP Neumann","year":"2003","unstructured":"Neumann, H. P. et al. Hemolytic uremic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J. Med. Genet. 40, 676\u2013681 (2003).","journal-title":"J. Med. Genet."},{"key":"BFnrneph201699_CR95","first-page":"285","volume":"21","author":"MR Duvvari","year":"2015","unstructured":"Duvvari, M. R. et al. Analysis of rare variants in the CFH gene in patients with the cuticulardrusen subtype of age-related macular degeneration. Mol. Vis. 21, 285\u2013292 (2015).","journal-title":"Mol. Vis."},{"key":"BFnrneph201699_CR96","first-page":"3861","volume":"24","author":"D Kavanagh","year":"2015","unstructured":"Kavanagh, D. et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum. Mol. Genet. 24, 3861\u20133870 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneph201699_CR97","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","volume":"27","author":"F Bu","year":"2016","unstructured":"Bu, F. et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J. Am. Soc. Nephrol. 27, 1245\u20131253 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR98","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1681\/ASN.2007080923","volume":"19","author":"R Martinez-Barricarte","year":"2008","unstructured":"Martinez-Barricarte, R. et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 19, 639\u2013646 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR99","unstructured":"KDIGO AKI Work Group. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int. Suppl. 2, 1\u2013138 (2012)."},{"key":"BFnrneph201699_CR100","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/ndt\/gfn063","volume":"23","author":"T Kwon","year":"2008","unstructured":"Kwon, T. et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated hemolyticuremic syndrome. Nephrol. Dial. Transplant. 23, 2088\u20132090 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201699_CR101","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0030-1262884","volume":"36","author":"C Skerka","year":"2010","unstructured":"Skerka, C. et al. The autoimmune disease DEAP-hemolytic uremic syndrome. Semin. Thromb. Hemost. 36, 625\u2013632 (2010).","journal-title":"Semin. Thromb. Hemost."},{"key":"BFnrneph201699_CR102","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-6143.2009.02870.x","volume":"10","author":"AM Waters","year":"2010","unstructured":"Waters, A. M. et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am. J. Transplant. 10, 168\u2013172 (2010).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201699_CR103","first-page":"458","volume":"2","author":"A Lionet","year":"2009","unstructured":"Lionet, A. et al. A case of adult atypical hemolytic uremic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2, 458\u2013460 (2009).","journal-title":"NDT Plus"},{"key":"BFnrneph201699_CR104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2215\/CJN.04680513","volume":"9","author":"ME Williams","year":"2014","unstructured":"Williams, M. E. & Balogun, R. A. Principles of separation: indications and therapeutic targets for plasma exchange. Clin. J. Am. Soc. Nephrol. 9, 181\u2013190 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","volume":"63","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri, F. et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am. J. Kidney Dis. 63, 40\u201348 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201699_CR106","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","volume":"29","author":"S Johnson","year":"2014","unstructured":"Johnson, S. et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr. Nephrol. 29, 1967\u20131978 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR107","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169\u20132181 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201699_CR108","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht, C. et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 87, 1061\u20131073 (2015).","journal-title":"Kidney Int."},{"key":"BFnrneph201699_CR109","first-page":"821A","volume":"24","author":"LA Greenbaum","year":"2013","unstructured":"Greenbaum, L. A. et al. Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric atypical hemolytic uremic syndromepatients [abstract]. J. Am. Soc. Nephrol. 24, 821A\u2013822A (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR110","first-page":"751A","volume":"25","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri, F. et al. Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-year update [abstract]. J. Am. Soc. Nephrol. 25, 751A (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2015","unstructured":"Loirat, C. et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 31, 15\u201339 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR112","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3109\/0886022X.2014.917574","volume":"36","author":"H Green","year":"2014","unstructured":"Green, H. et al. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren. Fail. 36, 1119\u20131121 (2014).","journal-title":"Ren. Fail."},{"key":"BFnrneph201699_CR113","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ped.12469","volume":"57","author":"M Hisano","year":"2015","unstructured":"Hisano, M. et al. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy. Pediatr. Int. 57, 313\u2013317 (2015).","journal-title":"Pediatr. Int."},{"key":"BFnrneph201699_CR114","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber, J. et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am. J. Transplant. 12, 3337\u20133354 (2012).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201699_CR115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1467-7652.2010.00552.x","volume":"9","author":"A Buttner-Mainik","year":"2011","unstructured":"Buttner-Mainik, A. et al. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol. J. 9, 373\u2013383 (2011).","journal-title":"Plant Biotechnol. J."},{"key":"BFnrneph201699_CR116","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4049\/jimmunol.1300269","volume":"191","author":"M Hebecker","year":"2013","unstructured":"Hebecker, M. et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J. Immunol. 191, 912\u2013921 (2013).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR117","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","volume":"190","author":"CQ Schmidt","year":"2013","unstructured":"Schmidt, C. Q. et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J. Immunol. 190, 5712\u20135721 (2013).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR118","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/ndt\/gfr436","volume":"26","author":"N Lorcy","year":"2011","unstructured":"Lorcy, N., Rioux-Leclercq, N., Lombard, M. L., Le Pogamp, P. & Vigneau, C. Three kidneys, two diseases, one antibody? Nephrol. Dial. Transplant. 26, 3811\u20133813 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201699_CR119","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1111\/petr.12273","volume":"8","author":"P Khandelwal","year":"2014","unstructured":"Khandelwal, P. et al. Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr. Transplant. 8, e134\u2013e139 (2014).","journal-title":"Pediatr. Transplant."},{"key":"BFnrneph201699_CR120","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1111\/petr.12519","volume":"19","author":"J Hofer","year":"2015","unstructured":"Hofer, J. et al. Successful living-related renaltransplantationin a patient with factor H antibody-associated atypical hemolytic uremic syndrome. Pediatr. Transplant. 19, e121\u2013e125 (2015).","journal-title":"Pediatr. Transplant."},{"key":"BFnrneph201699_CR121","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1111\/petr.12537","volume":"1","author":"R Grenda","year":"2015","unstructured":"Grenda, R. et al. Favorable four-yr outcome after renaltransplantationin a patient with complement factor H antibody and CFHR1\/CFHR3 gene mutation-associated HUS. Pediatr. Transplant. 1, e130\u2013e134 (2015).","journal-title":"Pediatr. Transplant."},{"key":"BFnrneph201699_CR122","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","volume":"27","author":"J Zuber","year":"2013","unstructured":"Zuber, J. et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant. Rev. 27, 117\u2013125 (2013).","journal-title":"Transplant. Rev."},{"key":"BFnrneph201699_CR123","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.imlet.2014.01.014","volume":"160","author":"M J\u00f3zsi","year":"2014","unstructured":"J\u00f3zsi, M. et al. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunol. Lett. 160, 163\u2013171 (2014).","journal-title":"Immunol. Lett."},{"key":"BFnrneph201699_CR124","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.molimm.2014.07.017","volume":"63","author":"R Watson","year":"2015","unstructured":"Watson, R. et al. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical hemolytic uremic syndrome (aHUS). Mol. Immunol. 63, 287\u2013296 (2015).","journal-title":"Mol. Immunol."},{"key":"BFnrneph201699_CR125","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.175.4.939","volume":"175","author":"S Meri","year":"1992","unstructured":"Meri, S., Koistinen, V., Miettinen, A., Tornroth, T. & Seppala, I. J. T. Activation of the alternative pathway of complement by monoclonal \u03bb light chains in membranoproliferative glomerulonephritis. J. Exp. Med. 175, 939\u2013950 (1992).","journal-title":"J. Exp. Med."},{"key":"BFnrneph201699_CR126","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.163.8.4590","volume":"163","author":"TS Jokiranta","year":"1999","unstructured":"Jokiranta, T. S., Solomon, A., Pangburn, M. K., Zipfel, P. F. & Meri, S. Nephritogenic \u03bb light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163, 4590\u20134596 (1999).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR127","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.07110810","volume":"6","author":"S Sethi","year":"2011","unstructured":"Sethi, S. et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin. J. Am. Soc. Nephrol. 6, 1009\u20131017 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR128","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2215\/CJN.06180710","volume":"6","author":"F Bijoux","year":"2011","unstructured":"Bijoux, F. et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin. J. Am. Soc. Nephrol. 6, 2165\u20132174 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR129","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","volume":"30","author":"A Payette","year":"2015","unstructured":"Payette, A. et al. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr. Nephrol. 30, 1033\u20131037 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201699_CR130","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1093\/ndt\/gfr422","volume":"26","author":"D Brackman","year":"2011","unstructured":"Brackman, D. et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol. Dial. Transplant. 26, 3399\u20133403 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201699_CR131","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2215\/CJN.07900811","volume":"7","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin. J. Am. Soc. Nephrol. 7, 265\u2013274 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR132","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1053\/j.ajkd.2010.06.021","volume":"56","author":"S Sethi","year":"2010","unstructured":"Sethi, S. et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am. J. Kidney Dis. 56, 977\u2013982 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201699_CR133","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/01.ASN.0000115702.28859.A7","volume":"15","author":"MA Dragon-Durey","year":"2004","unstructured":"Dragon-Durey, M. A. et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 15, 787\u2013795 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR134","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","volume":"62","author":"L Zand","year":"2013","unstructured":"Zand, L. et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am. J. Kidney Dis. 62, 506\u2013514 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201699_CR135","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"Leung, N. et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120, 4292\u20134295 (2012).","journal-title":"Blood"},{"key":"BFnrneph201699_CR136","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1172\/JCI43343","volume":"120","author":"R Martinez-Barricarte","year":"2010","unstructured":"Martinez-Barricarte, R. et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 120, 3702\u20133712 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201699_CR137","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jmg.2005.038315","volume":"43","author":"MA Abrera-Abeleda","year":"2006","unstructured":"Abrera-Abeleda, M. A. et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J. Med. Genet. 43, 582\u2013589 (2006).","journal-title":"J. Med. Genet."},{"key":"BFnrneph201699_CR138","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.178.6.3831","volume":"178","author":"M Laine","year":"2007","unstructured":"Laine, M. et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J. Immunol. 178, 3831\u20133836 (2007).","journal-title":"J. Immunol."},{"key":"BFnrneph201699_CR139","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1681\/ASN.2015020184","volume":"26","author":"AS De Vriese","year":"2015","unstructured":"De Vriese, A. S., Sethi, S., Van Praet, J., Nath, K. A. & Fervenza, F. C. Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. J. Am. Soc. Nephrol. 26, 2917\u20132929 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201699_CR140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","volume":"66","author":"M Noris","year":"2015","unstructured":"Noris, M. & Remuzzi, G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am. J. Kidney Dis. 66, 359\u2013375 (2015).","journal-title":"Am. J. Kidney Dis."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.99","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T09:37:51Z","timestamp":1692437871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2016.99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,25]]},"references-count":140,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["BFnrneph201699"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2016.99","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,25]]},"assertion":[{"value":"25 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}